<div id="readability-page-1"><div><p>CSPC Pharmaceutical Group (SEHK:1093) has drawn fresh attention after securing regulatory approval in China for its Aprepitant Injection, a next generation NK 1 antagonist aimed at preventing postoperative nausea and vomiting in adults.</p> <p>See our latest analysis for CSPC Pharmaceutical Group.</p> <p>Investors appear to be responding to a mix of product approvals, the 2025 earnings release and ongoing capital returns. A 1 year total shareholder return of 80.59% and a 90 day share price return of 9.22% suggest momentum has been building off the current HK$9.71 level.</p> <p>If this kind of pharma driven story interests you, it could be a good moment to widen the lens and check out 128 healthcare AI stocks.</p> <p>So with earnings per share at CN¥0.3398, a proposed HK$0.15 dividend per share and the stock trading around HK$9.71, the question is whether this reflects an undervalued pharma company or a market that is already pricing in future growth.</p> <h2>Price to Earnings of 25.1x: Is it justified?</h2> <p>On a P/E of 25.1x at around HK$9.71, CSPC Pharmaceutical Group sits below its own estimated fair P/E level yet well above the Hong Kong pharmaceuticals sector average.</p> <p>The P/E multiple compares the share price to earnings per share and is a quick way to see how much investors are paying for each unit of profit. For a diversified pharma group with forecast earnings growth of 13.21% per year and high quality earnings, this kind of multiple often reflects expectations that profits will keep progressing rather than stall.</p> <p>Here, the stock is described as good value versus an estimated fair P/E of 28.4x. This suggests the market is applying a lower earnings multiple than that fair ratio implies it could support. At the same time, the current 25.1x P/E sits well above the Hong Kong pharmaceuticals industry average of 15.4x, so the shares trade at a clear premium to sector peers that investors would need to weigh against the earnings and cash flow profile.</p> <p>Explore the SWS fair ratio for CSPC Pharmaceutical Group</p> <p><strong>Result: Price-to-Earnings of 25.1x (UNDERVALUED)</strong></p> <p>However, you still need to keep an eye on pricing pressure in Mainland China and any slowdown in annual revenue and net income growth that could challenge the current premium P/E ratio.</p> <p>Find out about the key risks to this CSPC Pharmaceutical Group narrative.</p> <h2>Another view using our DCF model</h2> <p>The P/E ratio paints one picture, but the Simply Wall St DCF model offers a different angle. With the share price at HK$9.71 and the model indicating a future cash flow value of HK$17.67, the stock screens as significantly undervalued. Which lens do you trust more when pricing risk and potential?</p> <p>Look into how the SWS DCF model arrives at its fair value.</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2eed9e3a-4933-4dbd-a9dd-48e09a572357/chart/dcf/query-ZGF0ZT0yMDI2LTA0LTA2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2eed9e3a-4933-4dbd-a9dd-48e09a572357/chart/dcf/query-ZGF0ZT0yMDI2LTA0LTA2"/><figcaption>1093 Discounted Cash Flow as at Apr 2026</figcaption></figure><p>Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out CSPC Pharmaceutical Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 247 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.</p> <h2>Next Steps</h2> <p>Mixed signals or a clear opportunity: the story only really comes together once you look under the hood yourself and weigh both sides. Act while the data is fresh and see how the 2 key rewards and 1 important warning sign</p> <h2>Looking for more investment ideas?</h2> <p>If you are serious about building a stronger portfolio, now is the time to broaden your watchlist with fresh ideas that match your risk and income goals.</p> <ul> <li>Supercharge your hunt for quality by scanning 247 high quality undervalued stocks that pair solid fundamentals with prices the market may not fully appreciate yet.</li> <li>Strengthen your income stream by reviewing 486 dividend fortresses that focus on higher yielding companies with the potential to support regular payouts.</li> <li>Protect your capital by filtering for 283 resilient stocks with low risk scores designed to highlight businesses with more resilient risk profiles.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><div><p>• Dividend Powerhouses (3%+ Yield)<br/>• Undervalued Small Caps with Insider Buying<br/>• High growth Tech and AI Companies</p><p>Or build your own from over 50 metrics.</p></div><p>Explore Now for Free</p></div></div></div>

520690

159570

159316

<p>CSPC Pharmaceutical Group (SEHK:1093) has received regulatory approval for its Aprepitant Injection, aimed at preventing postoperative nausea and vomiting. The stock has shown strong performance with an 80.59% total shareholder return over the past year. Currently trading at HK$9.71, the company has a P/E ratio of 25.1x, which is below its estimated fair P/E of 28.4x but above the sector average of 15.4x. Analysts suggest the stock may be undervalued, with a DCF model indicating a future cash flow value of HK$17.67. Investors are advised to consider both the potential and risks involved.</p>

Simplywall

Bosera Hang Seng SCHK Innovative Drug Select ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Guotai CSI Bio-medicine ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Yinhua CSI Innovative Drugs Industry ETF

Hwabao WP CSI Pharmaceuticals ETF

Penghua CSI HK Connect Health Care Composite ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

CSPC PHARMA

GF CSI HK Innovative Drugs Industry ETF(QDII)

ChinaAMC SSE Health Care ETF Initiating Fund

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

CSPC Pharmaceutical Group (SEHK:1093) Valuation Check After Aprepitant Injection Approval